Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.

This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5% FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.     

Effect of high doses of a sustained-release bovine somatotropin on antibody formation in dairy cows.

Eighty-two lactating Holstein cows received either one, three, or five concurrent, intramuscular injections of a unit dose (.6 g) of zinc methionyl bST (some-tribove) or five doses of the vehicle. Injections were administered at 14-d intervals from 60 d postpartum until the end of lactation or necropsy. Thirty-eight cows continued on the same treatment for a 2nd yr. Blood bST antibodies developed within the first 7 wk of treatment, and the number of cows with anti-bST binding generally declined with time. Thirteen out of 59 cows receiving bST developed binding activity > 25% (positives) during the 1st yr. At the .6-g dose level, no binding was detected after wk 15. Seven of the 13 positive cows were among the group randomly selected to continue on study during yr 2. In the 2nd yr, only 2 out of 24 bST-treated cows were positive. Binding activity was associated with the IgG fraction in serum. Binding capacities of antibodies ranged from .625 to 3.04 mg of bST/L, and affinities ranged from 1.14 x 10(8) to 3.14 x 10(8) L/mol. Cows considered to be clinically positive had performance similar to those of their herdmates having binding < 25%. No evidence of a pathologic effect of antibodies existed in treated cows, their calves, or fetuses. The presence of anti-bST antibodies did not affect milk production of the cow or growth of the calves conceived during bST treatment.     

Health and reproductive performance of dairy cows treated for up to two consecutive lactations with bovine somatotropin

Forty-three purebred Holstein cows were put on an rbST milk production trial. There were 15 control cows (saline-injected), 15 cows injected with 10.3 mg rbST/d and 13 cows injected with 20.6 mg rbST/d. Injections were initiated between wk 4 and 5 of lactation and continued for 266 consecutive days. Fourteen of the rbST-treated cows were treated with one of three dosages of rbST in the previous lactation (10.3, 20.6, or 41.2 rbST/d). The objective of this study was to determine the health and reproductive efficiency of cows treated with rbST for up to two consecutive lactations relative to control cows. The incidence of 11 health-related variables before, during, and after the 38-wk injection period were not different among treatment groups. Previous treatment with rbST had no effect on reproductive variables; however, there was evidence that injections with the highest dosage of rbST in the current lactation resulted in lowered reproductive efficiency. It is possible that the effects of rbST on early lactation energy and nitrogen balance have confounding effects on the estrous cycle.     

Fertility of lactating dairy cows administered recombinant bovine somatotropin during heat stress

Administration of recombinant bovine somatotropin (bST) to lactating dairy cows during heat stress increases milk yield, but it also can increase body temperature and may therefore compromise fertility. However, it is possible that bST treatment could increase fertility during heat stress because it has been reported to increase fertility in lactating cows. In addition, bST increases secretion of insulin-like growth factor-I (IGF-I) that promotes embryo survival. The purpose of this study was to determine effects of bST on reproductive function in lactating dairy cows during heat stress. The experiment was conducted in southern Georgia from July to November 2005 using lactating Holstein cows (n = 276 for reproductive traits). For first service timed artificial insemination (TAI), cows were presynchronized with 2 injections of PGF_2α given 14 d apart followed by a modified Ovsynch protocol (GnRH and insemination at 72 h following PGF_2α). Pregnancy was diagnosed by using ultrasonography on d 29 and reconfirmed by palpation between d 45 and 80 post-TAI. Nonpregnant cows were resynchronized with the modified Ovsynch protocol and received a second TAI. Treatment with bST started 1 wk before the start of Ovsynch and continued at 2-wk intervals. Blood samples were collected from a subset of cows to determine IGF-I profiles immediately before the first bST injection, 1 wk later, and at d 35 of bST treatment. Rectal temperatures were assessed on d 29 of bST treatment. Pregnancy rates (d 45 to 80 post-TAI) did not differ between bST and control cows for first- (16.7 vs. 15.2%) or second-service TAI (14.8 vs. 17.2%). Plasma concentrations of IGF-I and milk yield were greater for bST-treated cows following the initiation of bST treatment and bST increased rectal and vaginal temperatures. Body condition score was less for bST-treated cows. In conclusion, treatment with bST during heat stress increased IGF-I concentrations, milk yield over time, and rectal and vaginal temperatures without affecting first- or second-service pregnancy rates. Thus, at least under certain housing conditions, bST can be used to improve milk yield during heat stress without compromising fertility.     

Lactational response of Jersey cows to bovine somatotropin administered daily or in a sustained-release formulation.

Twenty-four Jersey cows were administered either 0 or 15.5 mg of bST/d or 310 mg of bST/14 d to determine the effect on milk yield, milk composition, feed intake, and body weight. Administration of bST was from wk 14 through 42 postpartum. Cows were housed in a tie-stall barn and fed for ad libitum intake a TMR adjusted to one of two energy protein densities according to milk yield. Milk yield of cows administered bST daily or by sustained-released vehicle increased 27.6 and 24.7%, respectively, over that of control cows; FCM increased by 30.3 and 26.7%. Percentages of fat and protein in milk were unaffected by bST treatment. Dry matter intake of cows administered bST was greater than that of control cows, whether expressed as kilograms per day or as a percentage of body weight. Apparent efficiency of yield increased in cows administered bST. No significant change in body weight occurred; however, cows administered bST had lower body condition scores at 42 wk postpartum. This trial demonstrated comparable effects of bST on lactational performance when administered daily or in a 14-d sustained-release vehicle.     

Overall efficacy of chronically administered recombinant bovine somatotropin to lactating dairy cows

Recombinant bST at daily dosages of 0, 10.3, 20.6, and 41.2 mg/d were injected for 266 d into 8, 10, 9, and 9 Holstein cows, respectively. Treatment effects of recombinant bST were assessed for milk production traits, BW, blood components, and health and reproductive variables. Data reported compare controls to all bST-treated cows. There was an average increase of 18% in 3.5% FCM for bST versus control cows. This increase resulted in enhanced feed efficiency for bST cows, as their DM intakes were not elevated above those of the control cows. Recovery of BW was similar between control and bST groups. Milk composition was unaffected except for a slight decrease in protein percentage during the first 9 wk of treatment, and an elevated SCC between wk 19 and 28. Blood parameters were not different between control and bST cows, except for hematocrit, which decreased with bST treatment. The only health and reproductive parameters affected by bST were mastitis and days open, which were increased in the highest dosage groups.     

Somatotropin antibody formation in cows treated with a recombinant bovine somatotropin over two lactations

Blood plasma from cows treated with somidobove, a form of recombinant bovine somatotropin, was assayed for development of antibodies against the protein. Forty-three Holstein cows, selected from an animal safety study, were monitored. Cows were divided into four groups and treated with placebo, 960, 2880, or 4800 mg somidobove per dose at 28-d intervals during two successive lactation periods. Blood plasma was collected at intervals prior to and during the lactations, and levels of IgG antibody reactive with somidobove were determined in an enzyme-linked immunosorbent assay. Virtually all of the cows treated with somidobove developed low levels (less than 40 micrograms/ml) of antibody against somidobove. One or two cows from each group responded with some-what higher levels, ranging from 40 to 200 micrograms/ml. Responses generally increased during the first 3 mo of treatment, then decreased, and remained constant with continued treatment. There was no sign of a memory response within or among the lactation periods, and no adverse health effects or decreases in lactational performance were associated with antibody production.     

Use of recombinant bovine somatotropin for up to two consecutive lactations on dairy production traits

Fifteen (control) cows were injected with saline; 28 cows were treated with rbST (15 with 10.3 and 13 with 20.6 mg/d). Fourteen of the 28 treated cows had between injected with rbST in the previous lactation. A total of 29 cows in the present trial had not received rbST in previous lactation. Treatment injections were started between wk 4 and 5 of lactation and continued for 266 consecutive days. Milk production, fee intake and efficiency, and BW data were recorded for 3 wk before and 3 wk after a 38-wk rbST treatment period. Administration of rbST increased average FCM yields in the current lactation by 19%, increased feed energy intake by 7%, and decreased feed conversion (energy intake per unit FCM output) by 17%. Previous treatment with rbST did not significantly affect current milk production but caused a nonsignificant increase in feed intake and a significant, unfavorable, increase in feed conversion of 12%. The results suggest that the advantages of rbST in terms of increased milk yield are maintained for a second consecutive lactation of rbST administration. However, the advantages of rbST in terms of improved feed conversion may be substantially reduced in a second consecutive lactation of administration.     

Lactation, health, and reproduction of dairy cows receiving daily injectable or sustained-release somatotropin.

Seventy-four Holstein cows (26 primiparous) were utilized to compare the efficacy and safety of sustained-release versus daily injectable formulations of recombinant bST. Twenty-four control cows were injected biweekly with oil microsphere; 25 cows were injected biweekly with 350 mg of bST microsphere; and 25 cows were injected daily with 10.3 mg of bST. Injections were initiated between wk 4 and 5 of lactation and continued for 280 d. Administration of bST caused a moderate increase in milk and FCM production and improved the efficiency of feed and energy conversions. Most health-related and reproduction-related variables did not differ among treatment groups. However, incidence of teat and udder disorders and feet and leg problems tended to be higher during the 40-wk injection period for the bST-treated cows than for the control cows. Incidence of GnRH therapy and number of days to first service were higher for daily bST-treated cows than for controls. No differences existed between sustained-release and daily bST-treated cows for any parameters monitored.     

Lactation response of dairy cows receiving bovine somatotropin via daily injections or in a sustained-release vehicle

Three experiments were conducted to characterize metabolic and milk production responses of dairy cows receiving recombinantly derived bovine somatotropin administered either by daily injection or in a sustained-release vehicle. In Experiment 1, somatotropin (25 mg/d) purified by two methods was given by daily injection for 14 d and resulted in 3.5 and 3.8 kg/d more milk than controls. Percentages of fat and total solids in milk were also increased by somatotropin. Eleven hematology indices and 12 metabolites, minerals, and enzyme activities in serum were unaffected by somatotropin. In Experiments 2 and 3, somatotropin was administered in a sustained-release vehicle during an 84-d treatment period. In Experiment 2, administration of 960 mg of somatotropin at 28-d intervals increased milk and SCM yields by 4.1 and 3.3 kg/d compared with yields of controls. There were no significant differences in other production parameters. In Experiment 3, 320, 640, and 960 mg somatotropin were each administered in the sustained-release vehicle at intervals of 14, 21, and 28 d. An uninjected group served as control. Cows receiving somatotropin averaged 3.5 to 5.9 kg/d more milk than controls across all injection intervals. Among doses, milk yield was greater at 960 mg than at 320 or 640 mg. There were no significant differences in milk or SCM among injection groups. These experiments demonstrate the comparable efficacy of somatotropin when given by daily injections or in a sustained-release vehicle.     

Response to recombinant bovine somatotropin in dairy cows with different genetic merit for milk production

Thirty-nine multiparous cows obtained from two genetic lines were utilized to determine the effect of genetic merit on lactation response to long-term administration of recombinant bST. Cow index ranged from -70 to 456 (mean = 183) and -494 to -88 (mean = -288) kg milk for high and low genetic groups, respectively. Cows were blocked by calving date and randomly assigned to treatment within genetic group. Treatments were 0, 10.3, 20.6, and 30.9 mg somatotropin injected daily from wk 14 through 44 postpartum. Cows were fed one of two total mixed rations. Diet 1 (NE1 = 1.65 Mcal/kg, CP = 18%, and ADF = 22%) was fed from start of lactation to at least 4 wk after initiation of treatment. Cows were switched to diet 2 (NE1 = 1.56 Mcal/kg, CP = 16%, and ADF = 27%) when milk output fell below 25 kg/d. Forty-four week lactation yields were 9800 and 9447 kg milk; 364 and 354 kg fat; and 322 and 309 kg protein for high and low genetic groups, respectively. Milk, milk fat, or protein yield due to somatotropin did not differ between genetic groups. Increasing dosage of bST increased milk, 4% FCM, fat, and protein yields in a linear fashion. Percentages of fat and protein of milk were similar for all treatment groups. Body weight changes were not significantly different among treatments, but condition score changes decreased linearly with increasing dose of bST. Long-term treatment with recombinant bST had no apparent effect on incidence of health problems or reproduction.     

Short-term administration of bovine somatotropin to lactating dairy cows in a subtropical environment

Our objective was to evaluate response of lactating dairy cows to daily injections of bovine somatotropin during a subtropical summer. Ten Holstein cows, averaging 196 d in lactation, were used in a 30-d study. No treatment was imposed during d 1 to 10 (period 1) and d 21 to 30 (period 3). During d 11 to 20 (period 2), cows were injected daily with either 0 or 59 IU of pituitary-derived bovine somatotropin in 30 ml solution. Dry matter intake and milk yield and composition were measured daily. Jugular blood samples, taken on d 10, 15, 20, and 30, were analyzed for insulin, nonesterified fatty acids, urea nitrogen, and insulin-like growth factor-1. Body temperatures and respiration rates were measured at 1400 h on 4 or 5 d during each 10-d period. Data were analyzed using orthogonal contrasts. Contrast of period 1 plus period 3 vs. period 2 for treatment X days interaction was significant for milk yield, respiration rate, serum nonesterified fatty acids, and insulin-like growth factor-1. Under heat stress, cows injected with bovine somatotropin for 10 d produced 9.3% more milk than control cows with no change in feed intake. This increased production was accompanied by higher respiration rates (6%) and higher concentrations of serum nonesterified fatty acids (150%) and insulin-like growth factor-1 (222%).     

Effect of dietary energy and previous bovine somatotropin on milk yield, mastitis, and reproduction in dairy cows.

Thirty multiparous lactating Holstein cows were blocked according to time of calving and assigned to a 2 x 3 factorial arrangement of treatments in a randomized complete block design to evaluate the effects of two dietary energy concentrations either without or with bST (20.6 mg/d per cow) administered to cows that had not or had received bST during the preceding lactation. Subcutaneous injection of bST began 28 to 35 d postpartum and continued for 39 wk. The dietary energy concentration x bST interaction was not significant for any response variable. Compared with DMI of control cows, DMI was higher for cows receiving bST, being 1.6 and 2.4 kg/d higher for cows receiving bST for one and two lactations, respectively. Milk, fat, and protein yields were higher for cows receiving bST than for controls. Those receiving bST for a second lactation also produced more milk than controls until wk 20; thereafter, milk yields were similar to those of controls. Somatotropin administration had no adverse effect on udder health. Cows receiving bST tended to ovulate less regularly than controls, which may be attributed to their higher milk yield. However, BW gains during lactation were similar for all treatments, indicating that bST-treated cows built energy reserves for the subsequent lactation. Although energy concentrations of the diets had no significant impact on yield, the higher energy diet tended to depress milk fat concentration. Administration of bST to dairy cows for a second, consecutive lactation yielded responses similar for the first 20 wk of the study to those receiving bST for the first time. However, after wk 20, milk yield was less than that by cows receiving bST for the first lactation but similar to that of control cows.     

Hormonal responses to bovine somatotropin and dietary protein in early lactation dairy cows

The effects of bST injection and dietary protein level on blood hormone and metabolite concentrations were examined in four mature Holstein cows in a double crossover design. Cows were assigned at d 5 to 9 postpartum to receive daily injections of either a control (saline) solution or 20.6 mg of bST. Four 3-wk periods were used during which one cow from each group was fed a medium protein diet (17.1% CP), and the other received a high protein diet (23.6% CP). Injections of bST or control solutions began on d 0 of the second period. Intakes of DM were not influenced by dietary protein or bST injection. Milk yield tended to increase with increased CP level but was not affected by bST injection. Based on the rate and extent of decline in milk production after cessation of bST injection, the cows assigned to bST had lower milk production potential than control cows. Thus, the effect of bST injection apparently was to enhance milk yield to levels similar to those of controls. There were no significant CP level or bST injection effects on glucose, FFA, somatostatin, or somatotropin concentrations. Glucagon concentrations were higher in bST-treated cows. Concentrations of insulin-like growth factor-I were increased with increased CP level and also with bST injection. Significant effects of days on bST were observed for insulin, insulin-like growth factor-I, glucose, and FFA. Cows given bST injections and producing equal amounts of milk as control cows did not show major physiological differences in hormones and metabolites with the exception of insulin-like growth factor-I.     

Lactational responses of dairy cows fed unsaturated dietary fat and receiving bovine somatotropin.

Feeding unsaturated dietary fat to lactating dairy cows receiving bST may effectively alter the fatty acid composition of milk fat. This was tested using 16 Holstein cows assigned to one of four treatments during midlactation. Treatments were control, control diet with 15.5 mg of bST/d per cow, dietary fat from sunflower seeds and bST, or dietary fat from safflower seeds and bST. Diets were formulated to contain 19% CP and contained 25% corn silage, 25% alfalfa hay, and 50% concentrate mix on a DM basis. Milk yield was not significantly higher when bST was administered and increased with added fat diets (29.5, 32.7, 40.0, and 34.1 kg/d for the control, control with bST, sunflower seed with bST, and safflower seed with bST treatments, respectively). Percentage of milk fat was similar for all treatments. Concentrations of long-chain and unsaturated fatty acids in milk were increased slightly by bST and substantially with added fat. Milk protein percentages were not influenced by bST but were reduced by approximately .2 unit with added fat. Added unsaturated dietary fat coupled with bST increased milk yield and produced a greater concentration of unsaturated fatty acids in milk.     

Responses of dairy cows in early lactation to bovine somatotropin and ruminally inert fat

Bovine somatotropin (0 or 41.2 mg/d bST) and calcium salts of long-chain fatty acids (0 or .77 kg/d Ca-LCFA) were administered to 16 Holstein cows in early lactation. Cows remained on 0 or 41.2 mg/d bST for the entire 10 wk and received 0 or .77 kg/d Ca-LCFA in one of two 5-wk periods. Production data were recorded daily, milk fatty acids, and blood metabolites were determined once each period. Treatments did not affect feed intake. Fat-corrected milk (kg/d) and percentage of milk fat for cows receiving no supplementation, fatty acids alone, bST alone, and fatty acids and bST together were 33.8, 3.2; 33.5, 3.1; 37.4, 3.4; and 40.8, 3.5. Milk fatty acids below C16 were reduced with either bST or dietary fatty acids; C16 fatty acids were lower with bST but higher with dietary fatty acids; C18:0 fatty acids were reduced with dietary fatty acids; and C18:1 fatty acids were higher with either bST or dietary fatty acids. Blood acetoacetate concentrations were higher with both bST and dietary fatty acids, beta-hydroxybutyrate was not different, and FFA and insulin concentrations increased with bST. In this experiment, the energy supplied by Ca-LCFA acids enhanced the lactogenic effect of bST.     

Long-term evaluation of a prolonged-release formulation of N-methionyl bovine somatotropin in lactating dairy cows

Eighty Holstein cows (first, second, or third lactation) were used to evaluate the efficacy of a prolonged-release formulation for sometribove (n-methionyl bovine somatotropin). Cows were fed ad libitum a complete mixed diet and milked twice daily. Cows were allocated randomly by parity to two treatment groups receiving 500 mg sometribove in a prolonged release formulation or excipient at 14-d intervals starting at 60 +/- 3 d postpartum and continuing for 36 wk. Treatment with sometribove increased FCM yield to a similar extent (11.4%, +3.1 kg/d) in primiparous and multiparous animals. Milk content of lactose, fat, ash, and Ca was not affected, but protein and phosphorous were slightly greater (less than 5%) in milk from sometribove-treated cows. Within a 14-d injection interval, animals treated with sometribove displayed a cyclic pattern in milk yield, but a similar pattern was not evident in feed intake.     

Effect on production traits of bovine somatotropin for up to three consecutive lactations.

Thirteen (control) cows were injected daily with saline and 22 with bST (12 at 10.3 mg/d and 10 at 20.6 mg/d) through wk 5 to 42 of lactation. Nine of the treated cows had received bST in the previous lactation, and 7 cows received bST in the previous two lactations. All control cows and 6 treated cows had not previously received bST. Treatment with bST caused substantial increases in milk production, feed intake, and efficiency of feed conversion in the current lactation, which is consistent with previous trials. Increases in feed intake were established fully within 9 wk of starting bST administration, somewhat earlier than usually reported. Treatment with bST in one or two previous lactations caused a statistically significant 14% reduction in production and 8% reduction in efficiency of feed conversion during the first 9 wk of bST treatment in the current lactation; reductions observed later in lactation were not statistically significant. Differences for other traits were not statistically significant. In combination with earlier trials, these results suggest that, although bST has beneficial effects on production and efficiency traits, these benefits may be considerably lower in the second and subsequent lactations of bST use. However, carry-over effects on cows not receiving bST in the current lactation were not explored in this trial.     

Effects of recombinant bovine somatotropin on nutritional status of dairy cows during pregnancy and of their calves

Objectives of this trial were to evaluate effects of rbST on the nutritional status of 24 Holstein cows during pregnancy and of their calves from birth to weaning. All cows conceived during injection with either a placebo or 350 mg of rbST in a sustained-release vehicle every 14 d commencing 98 to 112 d postpartum for their entire lactation. In Experiment 1, blood samples were collected at 90, 180, and 270 d postconception in cows. Concentrations of urea, glucose, albumin, total proteins, Ca, P, insulin, cortisol, hemoglobin, and hematocrit were unaffected by treatment as well as BW, body condition scores, and energy balances at conception and during pregnancy. Days open and calving interval were not significantly different but were numerically increased by 31 d in rbST-injected cows. Nonesterified fatty acids, bST, and insulin-like growth factor-I in plasma were elevated significantly in rbST-injected cows. In Experiment 2, blood samples were collected at birth and at 1, 3, 5, and 7 wk in calves born from cows of Experiment 1. Circulating concentrations of glucose, nonesterified fatty acids, albumin, total proteins, hemoglobin, insulin, cortisol, bST, insulin-like growth factor-I, and hematocrit, blood pH, blood gases and buffer capacity, birth weight and rate of weight gain, height at withers, and heart girth from birth to weaning were not different due to treatment of dam. However, some parameters were significantly different based on age and sex. These data support previous assumptions that the magnitude of the modifications in nutrient partitioning produced by rbST do not affect the hierarchy of the partitioning process for the calf.     

Relationship of thermal status to productivity in heat-stressed dairy cows given recombinant bovine somatotropin

The responses of lactating Holstein cows to daily administration of bovine somatotropin (bST) were measured at thermoneutrality (Tn) and under both constant and cycled heat-stress conditions to determine the relationship between thermal status and bST-induced shifts in milk production. All tests included a 5-d acclimation period at Tn (18°C), followed by a 2-d increase in ambient temperature to 28.5°C. After d 3, ambient temperature was cycled between 28.5 (day) and 25.5°C (night) for 4 d. Daily injections with either 31 mg of bST or saline began on d 1 of the experiment. Milk production, feed intake, and respiratory rate (RR) were measured daily. Intraperitoneal, telemetric temperature transmitters were used for a continuous measure of core body temperature (T_core). Blood samples were collected during each phase to evaluate the changes in serum chemistry in response to bST and heat stress. Following a 15-d recovery, cows were switched across injection treatments and the study was repeated. Milk production decreased by ∼18.4% below the initial yield at Tn by the end of 7 d of heat challenge. Although a reduction in milk production occurred during heat stress in both groups, milk production was higher in bST-treated cows compared with control cows during periods of constant and cyclic heat. Likewise, bST treatment during the entire period increased the milk-to-feed ratio over the control level by ∼11.3%. Plasma insulin-like growth factor 1 and serum nonesterified fatty acids accompanied the increased growth hormone level with bST treatment (∼122.0 and 88.8%, respectively), whereas plasma urea nitrogen was reduced by ∼13.3% to reflect the shift to lipid metabolism. There was no difference in T_core of the treatment and control groups at Tn. Both bST and control cows increased RR and T_core above the Tn level by ∼94.8 and 2.9%, respectively, during constant heat, with a greater increase in T_core of bST-treated compared with control cows (∼0.6%). The increase in RR during heat stress preceded T_core by 1 d for both groups. During cyclic heat, T_core decreased by ∼0.4% compared with constant heat in both the control and bST-treated groups. Bovine somatotropin treatment increased milk production similarly during the Tn and heat-stress periods, ∼8.3% over the control; however, the bST-induced increase in milk-to-feed ratio was greatest during the continuous and cyclic heat-stress phases, ∼16.2%. This increase occurred together with the elevation in T_core.